Immuneering Corporation Investment Income, Interest
Immuneering Corporation (IMRX) reported Investment Income, Interest of $1.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- Immuneering Corporation investment income, interest for the quarter ending 2026-06-30 was $1.08M, a 234.18% increase year-over-year.
- Immuneering Corporation investment income, interest for the quarter ending 2026-03-31 was $1.36M, a 210.23% increase year-over-year.
- Immuneering Corporation investment income, interest for the quarter ending 2025-12-31 was $1.86M, a 348.19% increase year-over-year.
- Immuneering Corporation investment income, interest for the quarter ending 2025-09-30 was $415.83K, a 23.99% decline year-over-year.
- Immuneering Corporation investment income, interest for fiscal 2025 was $3.04M, a 17.20% increase from fiscal 2024.
- Immuneering Corporation investment income, interest for fiscal 2024 was $2.59M, a 28.10% decline from fiscal 2023.
- Immuneering Corporation investment income, interest for fiscal 2023 was $3.61M, a 255.56% increase from fiscal 2022.
- Immuneering Corporation investment income, interest for fiscal 2022 was $1.01M, a 497.09% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.08M 10-Q · filed 2026-08-05 | $2.44M 10-Q · filed 2026-08-05 | $4.30M derived: sum of 3 quarters · filed 2026-08-05 | $4.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $1.36M 10-Q · filed 2026-05-15 | $3.22M derived: sum of 2 quarters · filed 2026-05-15 | $3.64M derived: sum of 3 quarters · filed 2026-05-15 | $3.96M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $2.28M derived: sum of 2 quarters · filed 2026-03-06 | $2.60M derived: sum of 3 quarters · filed 2026-08-05 | $3.04M 10-K · filed 2026-03-06 |
| 2025-09-30 | $415.83K 10-Q · filed 2025-11-12 | $739.84K derived: sum of 2 quarters · filed 2026-08-05 | $1.18M 10-Q · filed 2025-11-12 | $1.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $324.01K 10-Q · filed 2026-08-05 | $762.53K 10-Q · filed 2026-08-05 | $1.18M derived: sum of 3 quarters · filed 2026-08-05 | $1.72M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $438.52K 10-Q · filed 2026-05-15 | $853.76K derived: sum of 2 quarters · filed 2026-05-15 | $1.40M derived: sum of 3 quarters · filed 2026-05-15 | $2.23M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $415.24K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-06 | $962.31K derived: sum of 2 quarters · filed 2026-03-06 | $1.79M derived: sum of 3 quarters · filed 2026-03-06 | $2.59M 10-K · filed 2026-03-06 |
| 2024-09-30 | $547.07K 10-Q · filed 2025-11-12 | $1.37M derived: sum of 2 quarters · filed 2025-11-12 | $2.18M 10-Q · filed 2025-11-12 | $2.93M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $826.10K 10-Q · filed 2025-08-13 | $1.63M 10-Q · filed 2025-08-13 | $2.39M derived: sum of 3 quarters · filed 2025-08-13 | $3.24M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $804.88K 10-Q · filed 2025-05-05 | $1.56M derived: sum of 2 quarters · filed 2025-05-05 | $2.41M derived: sum of 3 quarters · filed 2025-05-05 | $3.58M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | $754.14K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $1.61M derived: sum of 2 quarters · filed 2025-03-20 | $2.78M derived: sum of 3 quarters · filed 2025-03-20 | $3.61M 10-K · filed 2025-03-20 |
| 2023-09-30 | $855.53K 10-Q · filed 2024-11-13 | $2.02M derived: sum of 2 quarters · filed 2024-11-13 | $2.85M 10-Q · filed 2024-11-13 | $3.37M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.17M 10-Q · filed 2024-08-06 | $2.00M 10-Q · filed 2024-08-06 | $2.51M derived: sum of 3 quarters · filed 2024-08-06 | $2.74M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $831.27K 10-Q · filed 2024-05-07 | $1.35M derived: sum of 2 quarters · filed 2024-05-07 | $1.57M derived: sum of 3 quarters · filed 2024-05-07 | $1.71M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $516.17K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | $739.15K derived: sum of 2 quarters · filed 2024-03-01 | $881.95K derived: sum of 3 quarters · filed 2024-03-01 | $1.01M 10-K · filed 2024-03-01 |
| 2022-09-30 | $222.99K 10-Q · filed 2023-11-09 | $365.78K derived: sum of 2 quarters · filed 2023-11-09 | $498.29K 10-Q · filed 2023-11-09 | $641.17K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $142.80K 10-Q · filed 2023-08-03 | $275.30K 10-Q · filed 2023-08-03 | $418.19K derived: sum of 3 quarters · filed 2023-08-03 | $435.59K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $132.51K 10-Q · filed 2023-05-04 | $275.39K derived: sum of 2 quarters · filed 2023-05-04 | $292.79K derived: sum of 3 quarters · filed 2023-05-04 | $296.05K derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $142.88K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $160.28K derived: sum of 2 quarters · filed 2023-03-06 | $163.54K derived: sum of 3 quarters · filed 2023-03-06 | $169.90K 10-K · filed 2023-03-06 |
| 2021-09-30 | $17.40K 10-Q · filed 2022-11-10 | $20.66K derived: sum of 2 quarters · filed 2022-11-10 | $27.01K 10-Q · filed 2022-11-10 | $27.53K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $3.26K 10-Q · filed 2022-08-10 | $9.61K 10-Q · filed 2022-08-10 | $10.13K derived: sum of 3 quarters · filed 2022-08-10 | $11.28K derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $6.36K 10-Q · filed 2022-05-10 | $6.87K derived: sum of 2 quarters · filed 2022-05-10 | $8.02K derived: sum of 3 quarters · filed 2022-05-10 | $10.49K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $518.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $1.67K derived: sum of 2 quarters · filed 2022-03-10 | $4.14K derived: sum of 3 quarters · filed 2022-03-10 | $42.66K 10-K · filed 2022-03-10 |
| 2020-09-30 | $1.15K 10-Q · filed 2021-11-09 | $3.62K derived: sum of 2 quarters · filed 2021-11-09 | $42.14K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $2.47K 10-Q · filed 2021-09-09 | $40.99K 10-Q · filed 2021-09-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |